Product Images Tadalafil

This is a description of Tadalafil Tablets USP. The pack contains 30 film-coated tablets, with each tablet containing Tadalafil USP 5. The tablets should not be split and the entire dose should be taken. There are no specific instructions for dosage, but the recommended dosages could be found in the accompanying literature. The pack must be stored at temperatures between 15-25C°. This warning also advises people to keep it out of the reach of children. The manufacturer of these tablets is Burl Pharmaceuticals, LLC, and they are distributed by Aurobindo Pharma Limited in India. The pack comes with a ML Number Z2MNAP2008FR.*

NDC 35573-411-30 is a product of Aurobindo Pharma Limited that contains Tadalafil Tablets USP, a medication used for treating erectile dysfunction. It comes in tablet form and should be taken as prescribed by a doctor. The packaging includes 30 tablets and should be stored at a moderate temperature. The dosage should not exceed one tablet per day. Please refer to the provided literature for more information regarding dosage.*

This is a description of Tadalafil Tablets USP, with NDC 35573-412-30 identifier. Each tablet contains 20mg of Tadalafil, manufactured by Aurobindo Pharma Limited. The tablets are controlled by USP and should be stored at controlled room temperature. It is recommended to take one tablet per dose. The tablets should not be split. This product is dispensed in a high container with 30 tablets, and it's only available with prescription RXONLY WLN: 22MIAPRO0OFR. There is also additional text regarding printing and coding areas that are not relevant to the description of the product.*

This is a description of a medication called "Tadalafil Tablets USP" with a strength of 2.5mg. It is intended for once daily use and comes in a pack of 30 tablets, organized in two blisters of 15 tablets each. The medication is available only by prescription and should not be split, with the entire dose being taken. The provided text includes the manufacturer's product code (NDC 35573-409-38) and some illegible information that is not available for a useful description.*

The text describes a figure showing the mean maximal change in blood pressure in response to sublingual nitroglycerin at various time intervals after the last dose of Tadalafil 20mg or placebo. The figure includes measurements of standing systolic and diastolic blood pressure, as well as supine systolic and diastolic blood pressure. The figure also includes a calculation of the difference between standing systolic and diastolic blood pressure.*

This is a study comparing the effects of taking Tadalfil 20mg and Doxazosin 8mg versus Placebo and Doxazosin 8mg on supine systolic blood pressure. The study presents a graph showing the mean change in systolic blood pressure over time between the two groups. No further information is available.*

The text contains a graph titled "Figure 4" showing plasma tadalafil concentration with respect to time, following single and multiple doses of 20 mg and 5 mg. The graph suggests that there's a difference between the concentrations following single doses and once-daily-doses of 5 mg. However, without additional context, it's difficult to understand the implications of this information.*

The text provides a chart displaying the mean IPSS changes in BPH patients by visit in Study J, with the duration of treatment in weeks plotted along the X-axis and the change from baseline in IPSS total score shown on the Y-axis. The chart compares the effects of Tatalafil 5 mg and a placebo on BPH patients.*

The text contains a graph with changes in IPSS scores over time for BPH patients taking Tadalafil and Finasteride. The x-axis represents the duration of therapy in weeks and the y-axis represents changes in IPSS scores from baseline. There are treatment groups for Tadalafil alone, Finasteride alone, placebo/Finasteride, and Tadalafil with Finasteride. The graph shows that the combination of Tadalafil and Finasteride resulted in the greatest improvement in IPSS scores over time.*